All World

Sanofi-Aventis wants to see the accounts of Genzyme

Sanofi-Aventis will report there on Genzyme's offer? The rumor was picked up again after the U.S. publication DealReporter said Wednesday that the case was seriously considered. According DealReporter, affiliated to the Financial Times, the French pharmaceutical giant would have mentioned a new bid at $ 71 per share.

A spokesman for Sanofi-Aventis joined Thursday morning would not comment on the rumor. But the group said it intends to continue its discussions with Genzyme, "he says, recalling that the laboratory has released a takeover offer for the U.S. company specialized in rare diseases Genzyme August 29 for $ 69 per share. The offer, valuing biotech to $ 18.5 billion (14.5 billion euros), was denied by Genzyme which considers inadequate.

The DealReporter says that raising the price to 71 dollars per share "was circulated during telephone conversations between the two companies last week. In exchange, Sanofi-Aventis would make a "partial due diligence" that would enable him to obtain additional information on the accounts of Genzyme.

Citing sources familiar with the matter, the DealReporter said such a rise is not sufficient to ensure that Sanofi-Aventis access to accounts from Genzyme.

ALSO READ:

"Sanofi would be willing to increase its offer for Genzyme

"Genzyme is salivating pharmaceutical sector